期刊文献+

HLA抗体的平均荧光强度值与补体C1q结合能力的相关性研究 被引量:3

Relationship between HLA antibodies strength and Clq binding ability
原文传递
导出
摘要 目的探讨HLA抗体的平均荧光强度值(MFI)预测补体Clq阳性的价值。方法研究对象为2012年1月至2014年1月31例等待肾移植的高致敏患者,留取患者血清样本,采用单抗原磁珠法检测患者HLA抗体及Clq结合的HLA抗体,分析HLA抗体的MFI与Clq阳性的相关性。结果31例患者中,单纯HLtA工类抗体阳性14例,单纯Ⅱ类抗体阳性12例,Ⅰ、Ⅱ类抗体均阳性5例。Ⅰ类和Ⅱ类抗体的MFl分别为7332±4490和9014±5885。Ⅰ类抗体中弱阳性、中度阳性和强阳性抗体分别为160个、190个和280个,Ⅱ类抗体则分别为132个、119个和285个。Ⅰ类抗体中有43.2%(272/630)的抗体能结合补体Clq,而Ⅱ类抗体为51.3%(275/536)(P=0.006)。Clq阳性HLA工类和Ⅱ类抗体的MFI(分别为11052±3291和13347±4076)显著高于Clq阴性HLAⅠ类和Ⅱ类抗体的MFI(分别为4506±2960和4448±3602)(P〈O.05)。Spearman相关性分析显示,HLA抗体MFI与同一抗体Clq的MFI具有相关性,其中工类抗体相关系数(r)=0.665,P〈0.01;Ⅱ类抗体r=0.761,P〈0.01。ROC分析显示,HLA抗体MFI能预测补体Clq阳性,其中工类抗体的曲线下面积(AuC)=0.917,Ⅱ类抗体的AUC=0.927。HLAⅠ类抗体MFI的截断值为8238,敏感性和特异性分别为82.4%和87.4%,阳性预测值为86.7%,阴性预测值为83.2%;Ⅱ类抗体MFI的截断值为6754,敏感性和特异性分别为90.9%和82%,阳性预测值为83.5%,阴性预测值为90.0%。结论HLA抗体的MFI能够预测补体Clq的结合。 Objective To investigate the relationship between HLA antibodies strength and complement-binding ability in sensitized renal patients waiting for renal transplantation. Method Serum samples of 31 sensitized renal patients waiting for renal transplantation were retrospectively analyzed by single-antigen bead array (SAB) to identify HLA antibodies and in parallel by Clq-SAB to determine the complement binding of HLA antibodies. Result Clq-positive HLA antibodies had significantly higher MFI than Clq-negative HLA antibody (for Class I, 11052 ±3291 vs. 4506± 2960, P〈0. 05;for Class II, 13347 ± 4076 vs. 4448±3602, P〈0. 05). The mean fluorescence intensities (MFI) of IgG-SAB were correlated with the MFI of Clq-SAB for the same antibodies (Spearman correlation; Class I, r = 0. 665, P 〈 0. 01 ; Class II, r = 0. 761, P 〈 0. 01 ). Receiver operating characteristics (ROC) curve analysis showed that the MFIs of HLA antibodies by IgG-SAB could predict their Clq-binding abilities [area under the curve (AUC)class Ⅰ= 0. 917; AUCclass Ⅱ = 0. 927). Using MFI cut-off value of 8238 and 6754 for HLA Class 1 and Class II antibodies, respectively, the sensitivity and specificity for Clq binding were 82. 4% and 87. 4% for Class Ⅰ antibodies, and 90. 9% and 82% for Class II antibodies, respectively. Conclusion The MFI of HLA antibodies by IgG-SAB can predict the Clq binding capability at a certain extent before transplantation.
出处 《中华器官移植杂志》 CAS CSCD 2015年第4期231-234,共4页 Chinese Journal of Organ Transplantation
基金 国家临床重点专科建设项目(201354401) 天津市卫生局科技基金(2013KY08) 公益性行业科研专项(201302009)
关键词 肾移植 HLA抗体 补体C1Q 单抗原磁珠法 Kidney transplantation HLA antibody Clq single-antigen bead array
  • 相关文献

参考文献16

  • 1赵杰,宋文利,莫春柏,王智平,付迎欣,郑建明,冯刚,杨涛,吴长利,沈中阳.C1q结合的供者特异性抗体预测高致敏患者肾移植后抗体介导的排斥反应[J].中华器官移植杂志,2014,35(11):668-671. 被引量:6
  • 2Yabu JM, Higgins JP, Chen G, et al. Clq-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation[J]. Transpantation,2011,91(33 : 342-347.
  • 3Loupy A, Lefaucheur C, Vernerey D, et al. Complement- binding anti-HLA antibodies and kidney-aUograft survival[J]. N Engl J Med, 2013, 369(13):1215-1226.
  • 4Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel Clq assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients[J]. J Heart Bung Transplant, 2011, 30(2) : 158-163.
  • 5Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients [J]. J Heart Lung Transplant, 2013,32(1) :98-105.
  • 6Kushihata F, Watanabe J, Mulder A, et al. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential[J]. Transplantation, 2004, 78(7): 995-1001.
  • 7Cecka JM, Zhang Q, Reed EF, et at. Preformed eytotoxic antibodies in potential allograft recipients: recent data[J]. Hum Immunol, 2005, 66(4): 343-349.
  • 8Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions[J]. Nat Rev Nephrol, 2010, 6(5): 297-306.
  • 9Otten HG, VerhaarMC, Borst HP, et al. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure [J]. Am J Transplant, 2012, 12(6) : 1618-1623.
  • 10Sutherland SM, Chen G, Sequeira FA, et al. Complement- fixing donor specific antibodies identified by a novel Clq assay are associated with allograft loss[J]. Pediatr Transplant, 2012, 16(1): 12-17.

二级参考文献12

  • 1Ceeka JM, Zhang Q, Reed EF, et al. Preformed cytotoxic antibodies in potential allograft recipients: recent data[J]. Hum Immunol, 2005, 66(4): 343-349.
  • 2Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor- specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy[J]. Transplantation, 2008, 86(6):820-825.
  • 3Phelan D, Mohanakumar T, Ramachandran S, et al. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay[J]. Hum Immunol, 2009, 70(8):584-588.
  • 4van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients[J]. Transplantation, 2008, 85(8):1086- 1090.
  • 5Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant[J]. Am J Transplant, 2012, 12(5): 1157-1167.
  • 6Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed CAd-fixing and non-CAd-fixing HLA single antigen reactivity in renal allograft recipients[J]. Transpl Int, 2009, 22(10) : 982-989.
  • 7Yabu JM, Higgins JP, Chen G, et al. Clq-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation[J]. Transplantation, 2011, 91(3): 342-347.
  • 8Loupy A, Lefaucheur C, Vernerey D, et al. Complement- binding anti-HLA antibodies and kidney-allograft survival[J]. N Engl J Med, 2013, 369(13) : 1215-1226.
  • 9Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel Clq assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients[J]. J Heart Lung Transplant, 2011, 30 (2) : 158- 163.
  • 10Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti- HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients[J]. J Heart Lung Transplant, 2013,32(1) :98-105.

共引文献5

同被引文献25

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部